Legal & General Group’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$799K Sell
182,860
-5,608
-3% -$26.5K ﹤0.01% 2212
2025
Q4
$952K Sell
188,468
-3,907
-2% -$18.1K ﹤0.01% 2231
2025
Q3
$668K Sell
192,375
-117,916
-38% -$443K ﹤0.01% 2360
2025
Q2
$1.05M Buy
310,291
+13,462
+5% +$44.9K ﹤0.01% 2222
2025
Q1
$1.19M Sell
296,829
-16,208
-5% -$84K ﹤0.01% 2121
2024
Q4
$2.03M Buy
313,037
+20,699
+7% +$123K ﹤0.01% 1975
2024
Q3
$1.62M Buy
292,338
+12,863
+5% +$72.9K ﹤0.01% 2057
2024
Q2
$1.56M Sell
279,475
-8,191
-3% -$49.2K ﹤0.01% 2054
2024
Q1
$1.93M Sell
287,666
-1,100
-0.4% -$8.7K ﹤0.01% 1958
2023
Q4
$2.63M Buy
288,766
+9,655
+3% +$60.8K ﹤0.01% 1809
2023
Q3
$1.54M Buy
279,111
+47,532
+21% +$381K ﹤0.01% 2010
2023
Q2
$1.98M Buy
231,579
+194,270
+521% +$1.74M ﹤0.01% 1936
2023
Q1
$343K Buy
37,309
+1,429
+4% +$15.4K ﹤0.01% 2423
2022
Q4
$366K Buy
35,880
+425
+1% +$5.71K ﹤0.01% 2415
2022
Q3
$522K Sell
35,455
-4,199
-11% -$54.5K ﹤0.01% 2333
2022
Q2
$425K Buy
39,654
+29,802
+302% +$297K ﹤0.01% 2381
2022
Q1
$106K Buy
9,852
+8,252
+516% +$111K ﹤0.01% 2849
2021
Q4
$26K Hold
1,600
﹤0.01% 3190
2021
Q3
$34K Buy
+1,600
New +$37.6K ﹤0.01% 3082

Other funds holding CTKB

Legal & General Group's CTKB Position: Q1 2026 in Review

Legal & General Group reduced its Cytek Biosciences (CTKB) stake by 3% in Q1 2026, selling an estimated $26.5K and leaving 182,860 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Legal & General Group first reported a position in CTKB in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.63M in Q4 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Legal & General Group held 182,860 shares of Cytek Biosciences worth $799K as of Q1 2026.
  • Legal & General Group sold 5,608 Cytek Biosciences shares in Q1 2026, an estimated $26.5K.
  • Cytek Biosciences made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2212 holding.
  • Legal & General Group first reported a position in Cytek Biosciences in Q3 2021 and has held it in 19 quarters since.
  • Legal & General Group's Cytek Biosciences position peaked at $2.63M in Q4 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.